These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 15684203

  • 21. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [Abstract] [Full Text] [Related]

  • 22. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP, Deray G, Héloire F.
    Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Summaries for patients. Cyclooxygenase-2 inhibitors and heart attacks: varying effects?
    Ann Intern Med; 2005 Feb 01; 142(3):I21. PubMed ID: 15684199
    [No Abstract] [Full Text] [Related]

  • 25. Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study.
    Gudbjornsson B, Thorsteinsson SB, Sigvaldason H, Einarsdottir R, Johannsson M, Zoega H, Halldorsson M, Thorgeirsson G.
    Eur J Clin Pharmacol; 2010 Jun 01; 66(6):619-25. PubMed ID: 20157701
    [Abstract] [Full Text] [Related]

  • 26. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.
    Arch Intern Med; 2005 Jan 24; 165(2):161-8. PubMed ID: 15668361
    [Abstract] [Full Text] [Related]

  • 27. The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.
    Warner JJ, Weideman RA, Kelly KC, Brilakis ES, Banerjee S, Cunningham F, Harford WV, Kazi S, Little BB, Cryer B.
    J Cardiovasc Pharmacol Ther; 2008 Dec 24; 13(4):252-60. PubMed ID: 18787084
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.
    Lévesque LE, Brophy JM, Zhang B.
    Ann Intern Med; 2005 Apr 05; 142(7):481-9. PubMed ID: 15809459
    [Abstract] [Full Text] [Related]

  • 31. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov 05; 38(11):81-6. PubMed ID: 11138599
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A, Krahn M, Naglie G.
    Arthritis Rheum; 2003 Jun 15; 49(3):283-92. PubMed ID: 12794781
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction.
    Brophy JM, Lévesque LE, Zhang B.
    Heart; 2007 Feb 15; 93(2):189-94. PubMed ID: 16849374
    [Abstract] [Full Text] [Related]

  • 36. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 15; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S, Spigset O, Slørdal L.
    Tidsskr Nor Laegeforen; 2005 Apr 07; 125(7):875-8. PubMed ID: 15815733
    [Abstract] [Full Text] [Related]

  • 39. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs.
    Phelan KM, Mosholder AD, Lu S.
    J Clin Psychiatry; 2003 Nov 07; 64(11):1328-34. PubMed ID: 14658947
    [Abstract] [Full Text] [Related]

  • 40. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
    Hudson M, Rahme E, Richard H, Pilote L.
    Arthritis Rheum; 2007 Apr 15; 57(3):516-23. PubMed ID: 17394181
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.